drugset
drugset / Trial / NCT02792491

Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over

NCT02792491 ↗

Phase 2 Unknown 57 enrolled Pusan National University Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is Phase II prospective trial of addition of rituximab to reduced dose CHOP chemotherapy in DLBC L patients aged 65 years and over.

Timeline

Start
2012-08
Primary completion
2017-12
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 600 mg/m2 Intravenous
Subject Doxorubicin Other / unclassified 30 mg/m2 Intravenous
Subject Prednisone Other / unclassified 40 mg Oral
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Subject Vincristine Small molecule 1 mg Intravenous

Indications

diffuse large B-cell lymphoma